Back to search

Netherlands· NL-58f116fdb901

DILABRO 85 microgram/43 microgram inhalatiepoeder in harde capsules

A indacaterol und glycopyrronium bromid product containing glycopyrroniumbromide + indacaterolmaleaat, registered in Netherlands by S.F Group S.r.l.. The same ATC class is registered in 11 of our 19 countries.

ATC R03AL04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedDILABRO 85 microgram/43 microgram inh…ATCR03AL04REGISTER NO.NL-58f116fdb901PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Indacaterol und glycopyrronium bromid is registered in 11 of 19 countries.

Countries holding a registration under ATC R03AL04 (indacaterol und glycopyrronium bromid), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Indacaterol und glycopyrronium bromid · ATC R03AL04

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
GLYCOPYRRONIUMBROMIDE + INDACATEROLMALEAAT
Manufacturer
S.F Group S.r.l.
Country
Netherlands (NL)
ATC code
R03AL04
ATC class
Indacaterol und Glycopyrronium bromid
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    134537

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b6363a42-0539-48c7-990e-00a09d2c9836
GET /v1/drugs/b6363a42-0539-48c7-990e-00a09d2c9836?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Inhalatiepoeder in harde capsule",
  "route": "Inhalatie",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h134537_smpc_en.pdf",
  "strength": null,
  "atc_label": "Indacaterol and glycopyrronium bromide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg134537",
  "excipients": [
    "CARRAGEENAN (E 407)",
    "HYPROMELLOSE (E 464)",
    "KALIUMCHLORIDE (E 508)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "TARTRAZINE (E 102)",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "GLYCOPYRRONIUMBROMIDE",
    "INDACATEROLMALEAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h134537_piluk.pdf",
  "authorised_at": "2026/09/07",
  "procedure_number": "NL/H/6308/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "134537",
  "additional_monitoring": "N"
}

See everything about indacaterol und glycopyrronium bromid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.